drugset / Trial / NCT01448772

Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions

NCT01448772

Phase 1 Completed 88 enrolled INSYS Therapeutics Inc
RandomizedCrossoverOpen-label

Summary

This is a comparative study to assess bioavailability of a proposed alternate dosage form against the current FDA-approved branded product.

Timeline

Start
2011-10
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dronabinol Other / unclassified 5 mg Oral

Indications

No indication recorded.